Vaccine Transitions for
Meningococcal A, C, Y, W Conjugate Vaccine
By the end of July 2022, Sanofi will be transitioning to MenQuadfi ™ as their sole meningococcal A, C, Y, W conjugate vaccine.
 |
|
MenQuadfi ™ is replacing Menactra®, not only in the US but worldwide. Once the inventory is depleted in the warehouse, Menactra® will no longer be available to order.
|
Keep in Mind:
MenQuadfi ™ is indicated for use in children 2 years of age and older. Beginning August 1st, provider orders for MCV4 vaccine to be used in children less than 2 years of age should place an order for Menveo®.
Resource Links:
CDC Recommended Child and Adolescent Immunization Schedule for age 18 years or younger, U.S. 2022
CDC Catch-up Immunization Schedule for persons aged 4 months – 18 years who start late or who are more than 1 month behind, U.S. 2022
MMWR Meningococcal Vaccination: Recommendations of the ACIP, 2020
Sanofi MenQuadfi ™ Package Insert
GSK - Menveo® Package Insert
The Arizona Immunization Program Office (AIPO) has clinical staff available to assist with your immunization questions (or contact your local county health department).
Michelina Stazzone, DNP, RN, CPNP Michelina.Stazzone@azdhs.gov, 480-259-5342
Sharon Sweeney, MPH, BSN Sharon.Sweeney@azdhs.gov, 480-261-5557
|
